SII and SIRI as Prognostic Biomarkers in Lupus Nephritis

Sex: All

Ages: 18 Years – 70 Years

Healthy volunteers: No

Enrollment: 100

Sponsor: Assiut University

Summary

This prospective observational study aims to evaluate the prognostic utility of the Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) as novel inflammatory biomarkers for monitoring disease activity and predicting renal progression, flares, and outcomes in patients with lupus nephritis.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria * Confirmed lupus nephritis according to ISN/RPS classification Exclusion Criteria: * Active infection, sepsis, or other concurrent inflammatory or autoimmune conditions * Malignancy or hematologic disorders affecting blood cell counts * Pregnancy * Use of medications significantly affecting blood counts (such as recent chemotherapy or G-CSF) * Incomplete medical records or anticipated loss to follow-up

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07780045). StuddyBuddy aggregates publicly available trial information.